肝细胞癌的化疗.pptVIP

谢谢! * * * The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma –Survival analysis of 3892 patients The Barcelona Clinic Liver Cancer (BCLC) staging offers prognostic stratification and treatment allocation for hepatocellular carcinoma (HCC).We conducted this retrospective study to assess the efficacy of different treatment options for patients with initial HCC diagnosis. Survival rate and median survival times associated with different treatment options in each stage of BCLC classification were compared using the Kaplan–Meier method and log-rank test. A total of 3892 patients were enrolled. Overall survival rates were 46.2% at 1 year and 16.6% at 5 years. The median survival times decreased from 57.7 months in very early stage to 1.6 months in terminal stage. Surgical resection offered the best survival benefit for patients in very early, early and even intermediate stages. Transarterial embolisation and conformal radiotherapy offered survival benefits for selected patients in advanced and terminal stages. In conclusion, following the treatment schedules allocated by BCLC staging had survival benefits for HCC patients. * * * * * - 国家食品药品监督管理局 (SFDA) * * 文章尚未发表 * HCC分子靶向治疗研究现状-大型III期临床试验纷纷失败 靶向药物 临床研究 例数 RR OS(m) ? Sorafenib III期-阳性 602 2.30% 10.7 vs 7.9(对照组) Llovet et al. N Engl J Med 2008 Cheng et al.Lancet Oncol 2009;10:25–34 226 - 6.5 vs 4.2(对照组) Sunitinib III期-失败 该试验因严重不良事件,及疗效未达到预设终点，于2010年4月22日终止，已在2011年ASCO上宣布失败 /ct2/show/NCErlotinib II期 38 9% 13 Philip et al. J Clin Oncol 2005 40 0% 6.3 Thomas et al. Cancer 2007 III期SEARCH - 失败 结果为阴性：跟安慰剂相比不能显著延长OS Andrew X. Zhu et al. ESMO 2012 Gefitinib II期 31 3% 6.5 ODwyer et al. J Clin Oncol 2006 Brivanib III期: BRISK PS – 失败 2011年底BMS公司宣布结果为阴性：跟安慰剂相比不能显著延长OS /ct2/show/NCterm=brivanib+HCCrank=4 III期: BRISK FL – 失败 2012年7月19日BMS公司宣布结果为阴性：跟安慰剂相比不能显著延长OS /file/115073/bristol-myers-brivanib-fails-in-ph-iii-liver-cancer-trial.